v3.26.1
Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details) - Kezar Life Sciences, Inc.
$ in Thousands
May 11, 2026
USD ($)
Asset Acquisition [Line Items]  
Cash and cash equivalents $ 56,811
Deferred tax assets 23,128
Interest receivable 55
Deferred tax benefits (23,128)
Accounts payable and accrued expenses (1,827)
Net assets acquired 55,039
Acquired in-process research and development 449
Total purchase consideration $ 55,488